Squarepoint Ops LLC grew its holdings in Sangamo Therapeutics Inc (NASDAQ:SGMO) by 184.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 174,740 shares of the biopharmaceutical company’s stock after purchasing an additional 113,232 shares during the period. Squarepoint Ops LLC owned about 0.15% of Sangamo Therapeutics worth $1,581,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also added to or reduced their stakes in SGMO. Steward Partners Investment Advisory LLC bought a new stake in shares of Sangamo Therapeutics during the second quarter worth $50,000. Virginia Retirement Systems ET AL boosted its stake in shares of Sangamo Therapeutics by 13.6% during the second quarter. Virginia Retirement Systems ET AL now owns 20,900 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 2,500 shares during the period. Creative Planning boosted its stake in shares of Sangamo Therapeutics by 91.1% during the second quarter. Creative Planning now owns 55,104 shares of the biopharmaceutical company’s stock valued at $593,000 after purchasing an additional 26,265 shares during the period. SG Americas Securities LLC bought a new position in shares of Sangamo Therapeutics in the second quarter worth about $229,000. Finally, Sector Gamma AS grew its holdings in shares of Sangamo Therapeutics by 5.4% in the second quarter. Sector Gamma AS now owns 251,698 shares of the biopharmaceutical company’s stock worth $2,711,000 after purchasing an additional 12,841 shares during the last quarter. Institutional investors and hedge funds own 70.83% of the company’s stock.
Several research analysts recently commented on SGMO shares. Cowen reaffirmed a “buy” rating on shares of Sangamo Therapeutics in a research note on Monday. Wedbush reissued a “hold” rating and issued a $11.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, November 12th. HC Wainwright initiated coverage on shares of Sangamo Therapeutics in a research note on Monday, August 26th. They issued a “buy” rating and a $16.00 target price on the stock. Zacks Investment Research lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 16th. Finally, BidaskClub raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 28th. Three equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Sangamo Therapeutics presently has an average rating of “Buy” and a consensus price target of $13.50.
SGMO opened at $10.31 on Tuesday. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.10. The stock’s fifty day moving average is $9.85 and its two-hundred day moving average is $10.27. The company has a market capitalization of $1.35 billion, a P/E ratio of -14.73 and a beta of 2.84. Sangamo Therapeutics Inc has a 52 week low of $6.26 and a 52 week high of $13.91.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.10. Sangamo Therapeutics had a negative return on equity of 30.33% and a negative net margin of 159.12%. The business had revenue of $21.96 million during the quarter, compared to analysts’ expectations of $12.16 million. During the same period in the prior year, the business earned ($0.13) EPS. The business’s revenue for the quarter was down 6.8% compared to the same quarter last year. Equities analysts anticipate that Sangamo Therapeutics Inc will post -1.2 earnings per share for the current year.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Featured Article: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.